Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
DMACthis companyDiaMedica Therapeutics Inc.	$9.64	-11.37×	6.66×	0×	-10.97×	-96.7%	0.0%	0.0%	0.0%	-58.4%	-61.0%	-7.8%	0×	0.47×	0×	11.81×	0.0%	1	37.36	2	C
AKBAAkebia Therapeutics, Inc.	$0.41	-77.4×	12.7×	1.75×	20.5×	-604.2%	83.3%	9.9%	-2.3%	-16.4%	9.3%	16.4%	6.63×	1.45×	0.97×	1.13×	0.0%	3	-5.78	1	D+
BIOABioAge Labs Inc.	$5.32	-5.91×	1.75×	52.85×	-3.66×	53.5%	100.0%	-1031.5%	-896.1%	-29.6%	-33.4%	-17.3%	0.02×	2.3×	-133.11×	14.24×	0.0%	3	4.79	2	C+
DNLIDenali Therapeutics Inc.	$20.17	-5.56×	2.86×	0×	-5.48×	-94.9%	0.0%	0.0%	0.0%	-50.6%	-52.6%	-14.6%	0.04×	0.34×	0×	9.16×	0.0%	3	2.05	2	C
MAZEMaze Therapeutics, Inc.	$34.69	-13.58×	5.02×	0×	-12.54×	-87.4%	0.0%	0.0%	0.0%	-36.9%	-37.7%	-6.3%	0.07×	1.29×	0×	15.5×	0.0%	3	11.54	2	C
MTVAMetaVia Inc.	$1.42	-1.15×	2.79×	0×	-0.37×	340.1%	0.0%	0.0%	0.0%	-243.3%	-21.6%	-105.6%	0.04×	0.78×	0×	1.93×	0.0%	0	-18.95	3	B
Peer median	—	-5.91×	2.86×	0×	-3.66×	-87.4%	0.0%	0.0%	0.0%	-36.9%	-33.4%	-14.6%	0.04×	1.29×	0×	9.16×	0.0%	3	2.05	2	—